255 related articles for article (PubMed ID: 27843031)
1. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
Rieber J; Abbassi-Senger N; Adebahr S; Andratschke N; Blanck O; Duma M; Eble MJ; Ernst I; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lohaus F; Lohr F; Petersen C; Schrade E; Streblow J; Uhlmann L; Wittig A; Sterzing F; Guckenberger M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):511-520. PubMed ID: 27843031
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
3. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
4. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
5. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry's experience.
Ricco A; Davis J; Rate W; Yang J; Perry D; Pablo J; D'Ambrosio D; Sharma S; Sundararaman S; Kolker J; Creach KM; Lanciano R
Radiat Oncol; 2017 Feb; 12(1):35. PubMed ID: 28143558
[TBL] [Abstract][Full Text] [Related]
6. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
8. Prognositc significance of SUV
Dong M; Liu J; Sun X; Xing L
J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in stereotactic body radiotherapy of lung metastases.
Borm KJ; Oechsner M; Schiller K; Peeken JC; Dapper H; Münch S; Kroll L; Combs SE; Duma MN
Strahlenther Onkol; 2018 Oct; 194(10):886-893. PubMed ID: 30014235
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
[TBL] [Abstract][Full Text] [Related]
13. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.
Baumann BC; Nagda SN; Kolker JD; Levin WP; Weber KL; Berman AT; Staddon A; Hartner L; Hahn SM; Glatstein E; Simone CB
J Surg Oncol; 2016 Jul; 114(1):65-9. PubMed ID: 27111504
[TBL] [Abstract][Full Text] [Related]
16. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
17. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
18. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity.
Baumann BC; Bernstein KA; DeLaney TF; Simone CB; Kolker JD; Choy E; Levin WP; Weber KL; Muniappan A; Berman AT; Staddon A; Hartner L; Van Tine B; Hirbe A; Glatstein E; Hahn SM; Nagda SN; Chen YL
J Surg Oncol; 2020 Oct; 122(5):877-883. PubMed ID: 32588468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
